Dashboard
With ROE of 15.20%, it has a very attractive valuation with a 3.05 Price to Book Value
- Over the past year, while the stock has generated a return of 17.84%, its profits have risen by 16.4% ; the PEG ratio of the company is 1.2
- At the current price, the company has a high dividend yield of 2.3
Stock DNA
Pharmaceuticals & Biotechnology
CNY 69,463 Million (Large Cap)
20.00
NA
2.35%
0.06
15.22%
2.88
Total Returns (Price + Dividend) 
Huadong Medicine Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

Huadong Medicine Adjusts Valuation Metrics, Signaling Strong Market Position and Growth Potential
Huadong Medicine Co., Ltd. has recently experienced a change in its evaluation, reflecting a shift in valuation metrics that highlight its competitive positioning in the Pharmaceuticals & Biotechnology sector. The company's solid fundamentals, including a notable return on equity and consistent profit growth, enhance its market appeal.
Read full news article Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2017
Shareholding Compare (%holding) 
Foreign Institutions
Held in 0 Schemes (0%)
Held by 1 Foreign Institutions (0.05%)
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
QoQ Growth in quarter ended Sep 2025 is 0.46% vs 2.44% in Jun 2025
QoQ Growth in quarter ended Sep 2025 is 5.53% vs -2.70% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 3.02% vs 7.74% in Dec 2023
YoY Growth in year ended Dec 2024 is 22.76% vs 12.39% in Dec 2023






